Forest Laboratories ($FRX) could well be playing a dirge at corporate headquarters today. The company's leading drug, Lexapro, now has new generic competition.
Generic competition has claimed another pharma plant. Sanofi ($SNY) plans to shutter a U.K. manufacturing facility by 2015, as demand erodes for products made there. Some 450 people work at the plant, Sky 's Tyne and Wear edition reports, and after higher-ups announced the closure plans Wednesday, the stunned workers went home for the day
AstraZeneca is seeking an injunction to block Seroquel copies at least until a court can review its claims. The drugmaker says the FDA shouldn't be allowed to usher generic Seroquel onto the market until Dec. 2, when data exclusivity expires.
The FDA has officially denied AstraZeneca's petition to hold off generic versions of its antipsychotic drug Seroquel.
Pharma's co-pay discounts have their fans--patients, certainly, but they also have their detractors.
Sun Pharmaceuticals ' at-risk launch of generic Protonix may prove to have been risky indeed. Pfizer's ($PFE) Wyeth unit slapped the Indian drugmaker with a $960 million damages claim, alleging Sun's
Lipitor just got shot down by a healthcare plan. As The Wall Street Journal reports, WellPoint ($WLP) is planning to stop covering Pfizer's ($PFE) brand-name cholesterol drug April 1, favoring its
The idea of facing generic competition for a $5 billion blockbuster like Diovan would daunt almost any CEO. But Joe Jimenez (photo) says his experience hawking baby food and ketchup at Heinz made him
AstraZeneca's ($AZN) layoffs announcement yesterday touched off more than its share of hand-wringing. It may be a straw-that-broke-the-camel's-back case; this shedding of 7,300 jobs follows a spate
Pfizer ($PFE) and Eli Lilly ($LLY) are continuing the downward-sloping earnings trend that's dominated Big Pharma's fourth-quarter reports. Pfizer saw profits drop by half, while Lilly's earnings